Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.40 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11588776 | 0.82 | GAA (0.50) | MAOBGAAGABBR2GABBR1 | |
| SCHEMBL10620750 | 0.82 | ALDH1A1 (0.51) | MAOBHTR2AHRH1CYP2D6 | |
| SCHEMBL11797661 | 0.79 | TRPM8 (0.47) | MEN1KMT2AOPRM1MAOBHTR2A | |
| SCHEMBL11671946 | 0.79 | SRC (0.43) | MEN1KMT2AOPRD1TDP1CYP2D6 | |
| SCHEMBL9853018 | 0.79 | MMP8 (0.45) | MEN1KMT2AOPRM1OPRD1CYP2D6 | |
| SCHEMBL10788440 | 0.78 | KDM4E (0.59) | GAA | |
| SCHEMBL16153014 | 0.76 | OPRD1 (0.41) | MEN1KMT2AOPRD1CYP2D6GAA | |
| SCHEMBL29069788 | 0.76 | ATM (0.43) | MEN1KMT2ACYP2D6GABBR2GABBR1 | |
| SCHEMBL9574998 | 0.74 | DAGLA (0.45) | MEN1KMT2ASRC | |
| SCHEMBL8585165 | 0.74 | HTR2A (0.48) | MEN1KMT2AOPRM1OPRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745413-B2 | Collection of traceable compounds and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-29 | — | — | US | disclosed |
| US-7745413-B2 | Collection of traceable compounds and uses thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-06-29 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-09-03 | — | — | US | disclosed |
| EP-1976841-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Neuromed Pharmaceuticals, Ltd. (CA) | 2008-10-08 | — | — | EP | disclosed |
| US-20080176763-A1 | Collection of Traceable Compounds and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-07-24 | — | — | US | disclosed |
| US-20080176763-A1 | Collection of Traceable Compounds and Uses Thereof | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-07-24 | — | — | US | disclosed |
| EP-1756119-B1 | COLLECTION OF TRACEABLE COMPOUNDS AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2007-10-10 | — | — | EP | disclosed |
| US-7244546-B2 | Planographic printing method and planographic printing plate precursor used therein | FUJIFILM CORPORATION (JP) | 2007-07-17 | — | — | US | disclosed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071035-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2007-06-28 | — | — | WO | disclosed |
| EP-0441226-A1 | (cyanomethyl)pyridines useful as PAF antagonists | J. URIACH & CIA. S.A. (ES) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221603-A1 | HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | RYR2, CACNA1E, RYR1 | MEN1 3119/4885KMT2A 2235/4885OPRM1 380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.